Tandem Diabetes Care (NASDAQ:TNDM) shares are surging on Friday following the company’s recent financial results and guidance for 2026.
The stock is moving higher as the broader market is experiencing positive momentum, with the Nasdaq up 0.62% today, contributing to the bullish sentiment.
Earnings Snapshot
Tandem Diabetes on Thursday reported a smaller-than-expected fourth quarter adjusted loss of one cent compared to the consensus loss of eight cents.
Sales increased 3% year over year to $290.4 million, beating the consensus of $277.03 million.
Adjusted gross profit jumped from 51% to 58%. The company reported adjusted operating profit of $8.3 million versus a loss $30.2 million reported a year ago.
Guidance
Tandem Diabetes forecasts fiscal 2026 sales of $1.065-$1.085 billion versus the consensus of $1.103 billion.
The company expects the adjusted EBITDA margin to be approximately 5% to 6%.
Management Commentary
“In 2026, our goal is to expand the worldwide market by delivering double-digit pump shipment growth. We are adopting a pay-as-you-go model in the U.S. that provides affordable access to customers, and progresses our business toward more predictable and profitable revenue that may not be evident in our 2026 sales expectations,” said Leigh Vosseller, executive vice president and CFO.
“We remain committed to improving margins and profitability during this transition that positions Tandem for accelerated sales growth in 2027 and beyond,” Vosseller commented on Thursday.
The broader market is experiencing gains, with the Technology sector up 0.44% today. Tandem Diabetes’ rise aligns with this positive trend, suggesting that the stock is benefiting from favorable market conditions as investors react to the company’s performance.
Technical Analysis
The stock is currently trading 12.5% above its 20-day simple moving average (SMA) and 15.3% above its 100-day SMA, indicating strong short-term momentum. Shares have increased 34.4% over the past 12 months and are currently positioned closer to their 52-week highs than lows.
The RSI is at 50.00, which is considered neutral territory, suggesting the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.15, below its signal line at 0.22, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $35
- Key Support: $20
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $25.17. Recent analyst moves include:
- Stifel: Hold (Raises target from $20 to $22 on Feb. 20)
- BofA Securities: Upgraded to Neutral from Underperform (Raises target to $30 from $15 on Feb. 20)
- Piper Sandler: Neutral (Raises target from $14 to $21 on Feb. 20)
- UBS: Neutral (Raises target from $17 to $22 on Feb. 20)
TNDM Price Action: Tandem Diabetes shares were up 37.53% at $25.47 at the time of publication on Friday, according to Benzinga Pro data.
